Correction: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation
Saved in:
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
BMJ Publishing Group
2020-12-01
|
| Series: | BMJ Open Gastroenterology |
| Online Access: | https://bmjopengastro.bmj.com/content/7/1/e000302corr1.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation
by: Emily Wright, et al.
Published: (2019-08-01) -
Impact of biological agents and tofacitinib for moderate-to-severe ulcerative colitis on health-related quality of life: a protocol for a network meta-analysis
by: Xueni Ma, et al.
Published: (2021-12-01) -
Efficacy And Safety Of Low Dose Tofacitinib As Induction Therapy In Moderate To Severe Ulcerative Colitis: A Pilot Study
by: Sadia Ahmed, et al.
Published: (2024-12-01) -
Network meta-analysis of efficacy and safety of drugs for the treatment of moderate to severe ulcerative colitis
by: Wenkai Zhang, et al.
Published: (2025-01-01) -
Effectiveness of tofacitinib in patients with ulcerative colitis: an updated systematic review and meta-analysis of real-world studies
by: Chuan Wan, et al.
Published: (2024-12-01)